Fig. 2From: Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor triala Best change and b change over time from baseline in sum of target lesion diameters in evaluable patients (n = 48). In a bars for individual patients are color-coded according to tumor PD-L1 status based on a 5% PD-L1 expression cutoff in tumor cells. In b lines for individual patients are color-coded based on confirmed best overall responseBack to article page